drugset / Trial / NCT05739188
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Phase 1/2
Unknown
18 enrolled
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
NaSequentialOpen-labelTreatment
Summary
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-GPRC5D CAR-T cells therapy for relapsed and refractory(r/r) multiple myeloma(MM).
Timeline
- Start
- 2023-02-07
- Primary completion
- 2025-02-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-GPRC5D CAR-T | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | Anti-GPRC5D CAR-T | Cell therapy | 6e+06 cells/kg | Intravenous |
| Subject | Anti-GPRC5D CAR-T | Cell therapy | 1e+07 cells/kg | Intravenous |